Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota. Show more

Location: 16305 36th Avenue North, Minneapolis, MN, 55446, United States | Website: https://www.celcuity.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

516.1M

52 Wk Range

$7.58 - $19.77

Previous Close

$13.62

Open

$13.57

Volume

171,554

Day Range

$13.35 - $13.94

Enterprise Value

398.5M

Cash

205.7M

Avg Qtr Burn

-25.56M

Insider Ownership

13.21%

Institutional Own.

82.08%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.